Abstract: Techniques of keyless authentication of computing services in distributed computing systems are disclosed herein. One example technique includes upon receiving a command to instantiate a computing service, transmitting a request to an authentication service for an identity assertion token corresponding to an application execution of which instantiates the computing service. The example technique can also include upon receiving the requested identity assertion token, storing the received identity assertion token in the container and modifying an entry of a configuration file in the container that allows the instantiated computing service to access the stored identity assertion token and authenticate to the authentication service using the identity assertion token.

Abstract: Described herein are methods for the treatment of cognitive impairment in a subject with a neurological autoimmune disease and methods for determining whether a subject who has a central nervous system autoimmune disease is likely to acquire a cognitive impairment.

Abstract: Described herein are methods for treating neurological autoimmune disorders in which the treatment method includes administering an immunoablative agent to eliminate most or essentially all maturing and mature elements of the immune system in an affected individual. Following this step, the individual is administered agents to reestablish the ablated immune system.

Abstract: The present invention provides methods of identifying subjects that are suitable and not suitable for high-dose cyclophosphamide treatment.

Abstract: Described herein are methods for the treatment of cognitive impairment in a subject with a neurological autoimmune disease and methods for determining whether a subject who has a central nervous system autoimmune disease is likely to acquire a cognitive impairment.

Abstract: The present invention relates to methods of treating an autoimmune disorder, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug in combination with immune therapeutics such as, for example, monoclonal antibodies that selectively bind B-cell specific antigens.

Abstract: The present invention provides methods of identifying subjects that are suitable for high-dose cyclophosphamide treatment.

Abstract: Provided are methods and compositions for treating and/or preventing an autoimmune diseases, including inflammatory bowel disease, rheumatoid arthritis, diabetes mellitus, celiac disease, autoimmune thyroid disease, autoimmune liver disease, Addison's Disease, Sjögren's Syndrome, transplant rejection, graft vs. host disease, or host vs. graft disease.